Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 11/20 | 0.75 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.72 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enkephalin SCHEMBL631958 | 1.00 | OPRD1 (0.75) | OPRD1OPRM1OPRK1 | |
| Enkephalin SCHEMBL631959 | 1.00 | OPRD1 (0.75) | OPRD1OPRM1OPRK1 | |
| Enkephalin SCHEMBL11399380 | 1.00 | OPRD1 (0.75) | OPRD1OPRM1OPRK1 | |
| Enkephalin SCHEMBL16189980 | 1.00 | OPRD1 (0.75) | OPRD1OPRM1OPRK1 | |
| Enkephalin SCHEMBL25236888 | 0.99 | OPRD1 (0.73) | OPRD1OPRM1OPRK1 | |
| Enkephalin SCHEMBL30400052 | 0.99 | OPRD1 (0.73) | OPRD1OPRM1OPRK1 | |
| Enkephalin SCHEMBL29458101 | 0.98 | OPRD1 (0.72) | OPRD1OPRM1OPRK1 | |
| SCHEMBL29355873 | 0.98 | OPRD1 (0.73) | OPRD1OPRM1OPRK1 | |
| Enkephalin SCHEMBL8580265 | 0.95 | OPRD1 (0.75) | OPRD1OPRM1OPRK1 | |
| SCHEMBL8077732 | 0.94 | OPRD1 (0.73) | OPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2972 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390490-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCERS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-11-28 | — | — | US | claimed |
| US-20240052418-A1 | METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-02-15 | — | — | US | claimed |
| US-11814681-B2 | Method for predicting a subjects response to SLC modulator therapy | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-14 | — | — | US | claimed |
| US-20230193348-A1 | DPP3 FOR THERAPY GUIDANCE, MONITORING AND STRATIFICATION OF NT-ADM ANTIBODIES IN PATIENTS WITH SHOCK | 4TEEN4 Pharmaceuticals GmbH (DE) | 2023-06-22 | — | — | US | claimed |
| US-20230158016-A1 | DELTA OPIOID RECEPTOR ANTAGONISTS REPROGRAM IMMUNOSUPPRESSIVE MICROENVIRONMENT TO BOOST IMMUNOTHERAPY | NATIONAL INSTITUTES OF HEALTH | 2023-05-25 | — | — | US | claimed |
| WO-2023044086-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCERS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-03-23 | — | — | WO | claimed |
| EP-4111204-A1 | DPP3 FOR THERAPY GUIDANCE, MONITORING AND STRATIFICATION OF NT-ADM ANTIBODIES IN PATIENTS WITH SHOCK | 4TEEN4 Pharmaceuticals GmbH (DE) | 2023-01-04 | — | — | EP | claimed |
| CN-115244401-A | DPP3 for therapy guidance, monitoring and stratification of NT-ADM antibodies in shock patients | 4TEEN4制药有限公司 | 2022-10-25 | — | — | CN | claimed |
| EP-4067370-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF PEPTIDES AND PEPTIDE RELATED COMPOUNDS | Yu, Chongxi (US) | 2022-10-05 | — | — | EP | claimed |
| US-20220133839-A1 | PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID PROBE(S) | TXP PHARMA GMBH (CH) | 2022-05-05 | — | — | US | claimed |
| US-5283236-A | Inclusion of permeation-enhancing agent | ORBON CORPORATION (US) | 1994-02-01 | — | — | US | claimed |
| US-5182258-A | Passage into nasolacrimal duct and absorption into circulation | ORBON CORPORATION (US) | 1993-01-26 | — | — | US | claimed |
| US-5156977-A | MONOCLONAL ANTIBODIES AGAINST ATRIAL, NATRIURETIC PEPTIDES OF HUMANS, HYBRIDOMAS & METHODS OF USE | BAYER AKTIENGESELLSCHAFT (DE) | 1992-10-20 | — | — | US | claimed |
| CN-1017349-B | Monoclonal antibody against human atrial natriuretic peptide | BAYER AG (DE) | 1992-07-08 | — | — | CN | claimed |
| EP-0195331-B1 | MONOCLONAL ANTIBODIES AGAINST ATRIAL NATRIURETIC PEPTIDES | BAYER AG (DE) | 1992-05-06 | — | — | EP | claimed |
| WO-1989009393-A1 | LUMINESCENT CHIMERIC PROTEINS | IGEN, INC. (US) | 1989-10-05 | — | — | WO | claimed |
| US-4801614-A | Process for using endogenous enkephalins and endorphins to inhibit growth of tumerous cells | TNI PHARMACEUTICALS, INC. (US) | 1989-01-31 | — | — | US | claimed |
| EP-0076676-B1 | PROCESS FOR USING ENDORPHINS AS ANTITUMOUR AGENTS | TNI PHARMACEUTICALS, INC. (US) | 1986-12-30 | — | — | EP | claimed |
| EP-0029300-B1 | POLYPEPTIDES, ANTISERA CONTAINING THEM AND METHODS OF THEIR USE | Addiction Research Foundation (US) | 1984-01-18 | — | — | EP | claimed |
| EP-0076676-A2 | Process for using endorphins as antitumour agents | TNI PHARMACEUTICALS, INC. (US) | 1983-04-13 | — | — | EP | claimed |